TIDMPOLX

RNS Number : 1084I

Polarean Imaging PLC

03 August 2023

3 August 2023

Polarean Imaging Plc

("Polarean" or the "Company")

Polarean Receives Clearance for New MRI Chest Coil

Additional clearance for new MRI chest coil further supports the recently announced collaboration with

Philips

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, announces it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's specialised MRI chest coil to now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 (129Xe) nuclei .

The Polarean XENOVIEW (TM) 3.0T Chest Coil is a flexible, single channel, transmit-receive RF coil tuned to image 129Xe nuclei while a patient is positioned inside a multinuclei-capable MRI scanner. The XENOVIEW Chest Coil is indicated to be used in conjunction with compatible 3.0T MRI scanners and approved hyperpolarised 129Xe for oral inhalation for the evaluation of lung ventilation in adults and paediatric patients, aged 12 years and older. The addition of the new Philips configuration does not affect the intended use of the device; the safety and effectiveness has been confirmed with testing.

Christopher von Jako, CEO of Polarean, said: "Polarean continues to develop and launch new devices and accessories that empower sites to perform modern respiratory imaging, enabling as many clinicians as possible to use our technology for their patients. This FDA clearance also further supports our recently announced collaboration with Philips, by expanding our product line to be compatible with their advanced MRI systems."

Enquiries:

 
  Polarean Imaging plc                                      www.polarean.com / www.polarean-ir.com 
  Christopher von Jako, Chief Executive                                            Via Walbrook PR 
   Officer 
  Kenneth West, Chairman 
 
  Stifel Nicolaus Europe Limited (NOMAD and 
   Sole Corporate Broker)                                                      +44 (0)20 7710 7600 
  Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare 
   Investment 
   Banking) 
  Nick Adams / Nick Harland (Corporate Broking) 
 
  Walbrook PR                                  Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
  Anna Dunphy / Phillip Marriage                                Mob: +44 (0)7876 741 001 / +44 (0) 
                                                                                      7867 984 082

About Polarean ( www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. The company also commercialises systems (such as the HPX hyperpolarisation system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.

PLC-RNS-2316

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKBBDQBKDAFK

(END) Dow Jones Newswires

August 03, 2023 02:00 ET (06:00 GMT)

Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Polarean Imaging Charts.
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Polarean Imaging Charts.